DCCR Shows ‘Life-changing’ Potential in Troubled Trial, Doctor Says in Interview

DCCR Shows ‘Life-changing’ Potential in Troubled Trial, Doctor Says in Interview

295430

DCCR Shows ‘Life-changing’ Potential in Troubled Trial, Doctor Says in Interview

Diazoxide choline controlled release (DCCR) tablets are an investigational therapy for Prader-Willi syndrome (PWS) that, according to data from a Phase 3 clinical trial and linked extension study, may be the first to control the disorder’s hallmark symptom: hyperphagia, or an insatiable hunger. But the COVID-19 pandemic that upturned societies worldwide affected top-line trial data, Soleno Therapeutics, its developer, argues in the face of a decision by the U.S. Food and Drug Administration (FDA) for…

You must be logged in to read/download the full post.